|Bid||35.90 x 900|
|Ask||36.00 x 800|
|Day's Range||35.60 - 36.40|
|52 Week Range||16.10 - 38.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.
NovoCure (NVCR) is mainly engaged in developing and bringing tumor treating fields for solid tumors to the market. The company’s first tumor treating fields delivery system, Optune, is targeted to treat adult patients with glioblastoma. Tumor treating fields use electric fields tuned to certain frequencies to disrupt solid tumor cancer cell division.
NovoCure (NVCR) generated revenues of $61.51 million in the second quarter—compared to $38.38 million in the second quarter of 2017. The growth was also driven by NovoCure’s initial launch efforts in Japan. NovoCure incurred a cost of revenues of $19.83 million in the second quarter—compared to $13.15 million in the second quarter of 2017.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Canopy Growth Corp (NYSE: CGC ) stock gained more ...
NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.
NovoCure (NVCR) is expected to incur SG&A (selling, general, and administrative) expenses of $35.4 million in the second quarter, compared with $31.38 million in the second quarter of 2017, an increase of 12.8%. NovoCure’s R&D (research and development) expenses are expected to increase 47.06% from $9.37 million in the second quarter of 2017 to $13.78 million in the second quarter. NovoCure’s total operating expenses are expected to increase 18.1% from $40.75 million in the second quarter of 2017 to $48.13 million in the second quarter.
NovoCure (NVCR) is expected to report its second-quarter earnings on July 26. In this series, we’ll look at the company’s top-line, operational, and bottom-line performance expected by analysts for the second quarter. We’ll also look at analysts’ recommendations and the performance of NovoCure stock so far this year.
Batting first and playing RF, we have GDS Holdings Ltd. (NASDAQ: GDS). GDS is one of the leading carrier-neutral data center solutions providers in China, and the growing demand for its services has led to impressive growth.
To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
NovoCure Limited made a small base pattern in 2016 and started a strong rally in 2017 and moving up four-fold from its 2017 nadir. Let's review the charts and indicators of NVCR to see what the prospects look like for this company.
Jim Cramer zooms through his take on callers' favorite stocks and lists his top picks in the cybersecurity space.
Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise?
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
On a per-share basis, the St. Helier, Jersey-based company said it had a loss of 23 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
NovoCure (NVCR) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
Investors are always looking for growth in small-cap stocks like NovoCure Limited (NASDAQ:NVCR), with a market cap of US$1.96B. However, an important fact which most ignore is: how financially healthyRead More...
NovoCure Limited’s (NASDAQ:NVCR): NovoCure Limited engages in the development, manufacture, and commercialization of Tumor Treating Fields for the treatment of solid tumors. The US$2.00B market-cap company announced a latest lossRead More...